Attilio Orazi, M.D.

Anatomic Pathology and Clinical Pathology

Publications

 

Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Pedersen LM, Møller MB: Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large b-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, Vincristine, and prednisone. J Clin Oncol 30:3460-7, 2012.

Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, et al: Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: a report from an International DLBCL Rituximab-CHOP Consortium Program study. Blood Sep 5 [Epub ahead of print], 2012.

 

Thiele J, Orazi A, Kvasnicka HM, Franco V, Boveri E, Gianelli U, Gisslinger H, Passamonti F, Tefferi A, Barbui T: European bone marrow working group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 97:e5-6; discussion e7-8, 2012.

 

Tripodo C, Sangaletti S, Guarnotta C,  Piccaluga PP,  Cacciatore M,  Giuliano M, Franco G, Chiodoni C, Sciandra M, Miotti S, Calvaruso G, Vetri V,  Carè A, Florena AM, Scotlandi K, Orazi A, Pileri SA, Colombo MP: Stromal SPARC Contributes to the detrimental fibrotic changes associated with myeloproliferation while its deficiency favors myeloid cell expansion. Blood Sep 5 [Epub ahead of print], 2012.

 

Chiu A, Orazi A: Mastocytosis and mastocytic overlap syndromes. Sem Diagn Pathol 29:19-30, 2012.

 

Czader M, Orazi A: World Health Organization classification of myelodysplastic syndromes. Curr Pharm Des 18:3149-62, 2012.

 

Boiocchi L, Arabadjief M, Ghanima W, Bussel JB, Orazi A, Geyer JT: Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. Mod Pathol  25:65-74, 2012.

 

Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, d'Amore ES, Li Y, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, et al:  Patients with diffuse large B cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP consortium program study. Haematologica Aug 28. [Epub ahead of print], 2012.

 

Courville EL, Wu Y, Kourda J, Roth CG, Brockmann J, Muzikansky A, Fathi AT, de Leval L, Orazi A, Hasserjian RP: Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Mod Pathol 26:751-61, June 2013.

 

Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, Liu WM,Miranda RN, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, et al: CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 121:2715-24, 2013.

Li Y, Gordon MW, Xu-Monette ZY, Visco C, Tzankov A, Zou D, Qiu L, Montes-Moreno S, Dybkaer K, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huang Q, Ai W, Ponzoni M, Ferreri AJ, Winter JN, Go RS, et al: Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood 121:4529-40, 2013. 

 

Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, et al: MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121:4021-31, 2013.

 

Frei E, Visco C, Xu-Monette ZY, Dirnhofer S, Dybkær K, Orazi A, Bhagat G, His ED, van Krieken JH, Ponzoni M, Go RS, Piris MA, Møller MB, Young KH, Tzankov A: Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. J Clin Pathol Epub ahead of print], Jun 17, 2013.

Mascarenhas JO, Orazi A, Bhalla KN, Champlin RE, Harrison C, Hoffman R:  Advances in myelofibrosis: a clinical case approach. Haematologica 98:1499-509, 2013.

Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ: Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 122:1881-6, 2013.

Geyer JT, Niesvizky R, Jayabalan DS, Mathew S, Subramaniyam S, Geyer AI, Orazi A, Ely SA: IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease. Mod Pathol doi: 10.1038/modpathol.2013.159. [Epub ahead of print], 2013.

 

Back to topBack To Top